UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10

 

GENERAL FORM FOR REGISTRATION OF SECURITIES

Pursuant to Section 12(g) of The Securities Exchange Act of 1934

 

 

 

CS DIAGNOSTICS CORP.

(Exact name of registrant as specified in its charter)

 

Wyoming 20-1290331

(State or other jurisdiction of incorporation or

organization)

(IRS Employer Identification No.)

 

Stresemannallee 4b Neuss, Germany 41460

(Address of principal executive offices)

 

+49 (0)2131 151 08 71

(Issuer’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act: Not Applicable

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, par value $0.001 per share

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o Accelerated filer o
Non–Accelerated filer o Small reporting company x
    Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

  
 

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10

 

Certain information required to be included herein is incorporated by reference to specifically-identified portions of the body of the information statement filed herewith as Exhibit 99.1. None of the information contained in the information statement shall be incorporated by reference herein or deemed to be a part hereof unless such information is specifically incorporated herein by reference.

 

Item 1. Business.

 

The information required under this item is contained under the sections of the information statement entitled “Business,” “Risk Factors,” “Security Ownership,” and “Capitalization.” Those sections are incorporated herein by reference.

 

Item 1A. Risk Factors.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 2. Financial Information.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors,” “Security Ownership,” “Description of Capital Stock,” and “Capitalization—Management’s Discussion and Analysis of Financial Condition and Results of Operation” and the financial statements referenced therein, of the Information Statement which sections are incorporated herein by reference.

 

Item 3. Properties.

 

The information required under this item is contained under the section of the information statement entitled “Business—Leased Offices.” Those sections are incorporated herein by reference.

 

Item 4. Security Ownership of Certain Beneficial Owners and Management.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors,” “Security Ownership,” “Directors, Executive Officers, and Corporate Governance,” “Description of Capital Stock,” and “Capitalization.” Those sections are incorporated herein by reference.

 

Item 5. Directors, Executive Officers and Corporate Governance.

 

The information required under this item is contained under the section of the information statement entitled “Security Ownership,” “Directors, Executive Officers, and Corporate Governance,” “Description of Capital Stock,” and “MD&A” Those sections are incorporated herein by reference.

 

Item 6. Executive Compensation.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors,” “Directors, Executive Officers, and Corporate Governance—Executive Compensation,” “Capitalization,” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 7. Certain Relationships and Related Transactions, and Director Independence

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors,” “Security Ownership,” “Directors, Executive Officers, and Corporate Governance—Stock and Stock Option Issuances in 2023 and 2024 and Related Party Transactions,” “Description of Capital Stock,” “Capitalization,” and “MD&A.” Those sections are incorporated herein by reference.

 

  
 

 

Item 8. Legal Proceedings.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors” and “Legal Proceedings.” Those sections are incorporated herein by reference.

 

Item 9. Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters.

 

The information required under this item is contained under the section of the information statement entitled “Business,” “Risk Factors,” “Security Ownership,” “Directors, Executive Officers, and Corporate Governance,” “Description of Capital Stock,” “Capitalization,” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 10. Recent Sales of Unregistered Securities.

 

The information required under this item is contained under the section of the information statement entitled “Risk Factors,” “Directors, Executive Officers, and Corporate Governance—Related Party Transactions,” “Description of Capital Stock—Recent Issuances of Securities,” “Capitalization,” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 11. Description of Registrant’s Securities to be Registered.

 

The information required under this item is contained under the section of the information statement entitled “Business—Overview,” “Risk Factors,” “Security Ownership,” “Directors, Executive Officers, and Corporate Governance,” “Description of Capital Stock,” “Capitalization,” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 12. Indemnification of Directors and Officers.

 

The information required under this item is contained under the section of the information statement entitled “Business,” “Risk Factors,” “Directors, Executive Officers, and Corporate Governance—Limitation of Liability and Indemnification,” and “MD&A.” Those sections are incorporated herein by reference.

 

Item 13. Financial Statements and Supplementary Data.

 

The information required under this item is contained under the section of the information statement entitled "Index to Financial Statements." This section is incorporated herein by reference.

 

Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 15. Financial Statements and Exhibits.

(a) Financial Statements. The information required under this item is contained under the section of the information statement entitled “Index to Financial Statements.” This section is incorporated herein by reference.

(b) Exhibits. The following documents are filed as exhibits hereto:

 

Exhibit No. Exhibit Description
3.1 Bylaws
3.2 Amended and Restated Preferred Series A Designation
3.3 Amended and Restated Preferred Series B Designation
3.4 Amended and Restated Preferred Series C Designation
10.1 PatientTrac Limited Securities Purchase Agreement, April 4, 2022
10.2 CS Interpharm Asset Purchase Agreement, September 4, 2023
99.1 Information Statement

 

  
 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Date: July 28, 2025 CS Diagnostics Corp.
   
  By: /s/Mohammad EsSayed
    Mohammad EsSayed
    Group CFO, VP

 

 

 

 

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 3.1

EXHIBIT 3.2

EXHIBIT 3.3

EXHIBIT 3.4

EXHIBIT 10.1

EXHIBIT 10.2

EXHIBIT 99.1